Quest Diagnostics (DGX)
(Delayed Data from NYSE)
$139.50 USD
+5.24 (3.90%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $139.54 +0.04 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
DGX 139.50 +5.24(3.90%)
Will DGX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for DGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DGX
Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down
Quest Diagnostics (DGX) Beats Q1 Earnings and Revenue Estimates
DGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Unlocking Q1 Potential of Quest Diagnostics (DGX): Exploring Wall Street Estimates for Key Metrics
Earnings Preview: Quest Diagnostics (DGX) Q1 Earnings Expected to Decline
Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?
Other News for DGX
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
FDA brings lab tests under federal oversight in bid to improve accuracy and safety
Quest Diagnostics, LabCorp climb following FDA testing oversight rule
Quest Diagnostics (DGX): A Comprehensive Analysis of Its Market Value
FDA brings lab tests under federal oversight in bid to improve accuracy and safety